To evaluate the efficacy of Compound Kushen Ointment in treating eczema and to explore its preliminary mechanism of action.Methods:Fifty-six male Kunming mice were randomly divided using a random number method into blank control group，model group，blank matrix group，positive drug group(Compound Dexamethasone Acetate Cream，0.75 mg/cm2)，and high-，medium-，and low-dose Compound Kushen Ointment groups(500，250，and 125 mg/cm2)，with eight mice in each group.Except for the blank control group，all other groups were sensitized with 2,4-dinitrochlorobenzene(DNCB) to establish an eczema mouse model.On the day of induction，treatment was initiated and continued for 14 days.Samples were collected 24 hours after the final administration.The skin lesions of the mice were scored.The thymus and spleen indices were calculated.Ear swelling was measured.Histopathological changes were observed via hematoxylin-eosin(HE) staining.Mast cells were examined using toluidine blue staining，and serum levels of interleukin-4(IL-4)，IL-5，IL-10，tumor necrosis factor-α(TNF-α)，and interferon-γ(IFN-γ) were assessed using enzyme-linked immunosorbent assay(ELISA).Results:Compared to the model group，all dosage groups of Compound Kushen Ointment showed varying degrees of reduction in skin lesions and ear swelling，along with thinning of the epidermis，a significant reduction in the number of mast cells，and decreased thymus and spleen indices.Eczema symptoms were alleviated，and serum levels of IL-4，IL-5，IL-10，TNF-α，and IFN-γ were significantly reduced(P<0.01，P<0.05).Conclusion:Compound Kushen Ointment has a significant therapeutic effect on eczema in mice，and its mechanism of action may be related to regulating inflammatory mediators，inhibiting inflammatory responses，and maintaining the balance of T-helper cell 1(Th1)/T-helper cell 2(Th2) homeostasis.